Cidofovir in the treatment of poxvirus infections.
Cidofovir in the treatment of poxvirus infections.
复制标题
Cidofovir治疗痘病毒感染。
DOI:
10.1016/s0166-3542(02)00008-6
复制
发表时间:
2002-07
影响因子:
7.6
通讯作者:
De Clercq, E
中科院分区:
文献类型:
--
作者:
De Clercq, E
关键词:
Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among the poxviruses, vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, molluscum contagiosum and orf have proven sensitive to the inhibitory effects of cidofovir. In vivo, cidofovir has shown high efficacy, even after administration of a single systemic (intraperitoneal) or intranasal (aerosolized) dose, in protecting mice from a lethal respiratory infection with either vaccinia or cowpox. Cidofovir has also demonstrated high effectiveness in the treatment of vaccinia virus infection in severe combined immune deficiency mice. In humans, cidofovir has been used successfully in the treatment, by both the topical and intravenous route, of recalcitrant molluscum contagiosum and orf in immunocompromised patients. Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia).
登录
查看更多内容
影响因子:
--
作者:
Meadows, KP;Tyring, SK;Rallis, TM
通讯作者:
Rallis, TM
影响因子:
6.4
作者:
Bray, M;Martinez, M;Huggins, JW
通讯作者:
Huggins, JW
影响因子:
3.1
作者:
Andrei, G;Snoeck, R;De Clercq, E
通讯作者:
De Clercq, E
影响因子:
12.7
作者:
NEYTS, J;DECLERCQ, E
通讯作者:
DECLERCQ, E
影响因子:
3.8
作者:
Lacy, SA;Hitchcock, MJM;Cundy, KC
通讯作者:
Cundy, KC